Drug Discovery World

DECEMBER 15, 2022

As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Early phase clinical trials for gene editing therapies.

Gene Editing 52

Gene Editing Gene In-Vivo Genome 52

pharmaphorum

FEBRUARY 3, 2021

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies.

Gene Editing 96

Gene Editing Gene DNA Engineer 96

Drug Discovery World

JULY 18, 2023

Nucleic acid-based diagnostics, which typically require PCR reagents and laboratory equipment, are crucial for identifying, treating, and preventing common infectious diseases. CRISPR diagnostics have successfully detected various pathogens, including RNA viruses (eg. Herpesviridae, Polyomaviridae, and Papillomaviridae), bacteria (e.g.,

DNA 98

DNA Genome Genomics RNA 98

Drug Discovery World

NOVEMBER 30, 2023

coli expression systems and is using high-throughput expression pipelines to screen constructs for optimal expression to generate protein and cellular reagents. The Absolute Antibody team was available to discuss custom services, as well as the company’s comprehensive antibody reagent catalogue.

Antibody 59

Antibody Protein Engineer In-Vivo 59